Abpro appoints Gavin MacBeath as CSO
Dr. MacBeath brings over 16 years of experience in academia and the biotechnology industry.
Dr. MacBeath comes to Abpro from Merrimack Pharmaceuticals, where he was a Founder and served most recently as Senior Vice President of Discovery and Head of Translational Medicine.
During this time, Dr. MacBeath also held a position as Lecturer / Principal Investigator in the Department of Systems Biology at Harvard Medical School, where he discovered new signaling pathways driving cancer metastasis.
Previously, Dr. MacBeath was an Associate Professor in the Department of Chemistry and Chemical Biology at Harvard University.
While at Harvard, he was a pioneer in Systems Biology, where he developed and used protein microarray technology to dissect aberrant signaling pathways in cancer.
Dr. MacBeath holds a Bachelor of Science Degree in Genetics from the University of Manitoba and a Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute. ■
LATEST MOVES FROM Massachusetts
- RXI Pharma names Gerrit Dispersyn chief development officer
- resTORbio appoints Joan Mannick as CMO
- C&W Services appoints Mike Losier as director
- Charles River Associates appoints Robert A. Whitman to board
- Ironwood Pharmaceuticals appoints Christopher Wright as SVP
More inside POST
Lukoil Q4 sales increased 7% Earnings